Serum antibodies against HERV-K-Env proteins have been reported to be present in some patients with cancer, such as lung cancer (14), breast cancer (30), and prostate cancer (31), but the antibody titer is generally low or absent in most patients with advanced cancer (14). Here, ERVW-1 is linked to breast carcinoma.